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Abstract 
Problem: The purpose of this project was to determine the most effective 
prophylactic antibiotic to decrease the number of patients who have urinary tract 
infections (UTIs) after pelvic floor reconstructive surgery in a gynecological 
reconstructive surgery practice.  
Methods: This was a retrospective chart review from 2015-2017 that included 732 
subjects from a single practice. All patients underwent pelvic floor reconstructive 
surgery, with or without a midurethral sling placed. Patients also had a catheter and 
vaginal packing postoperatively. Patients who had a culture-proven UTI within the six-
week postoperative period were noted. 
Results: There were less UTIs (χ2 = 12.119, df = 1, P = .000) in the 
fluoroquinolone cohort than in the other antibiotic cohort. Additionally, it was found that 
there was a statistically significant increase in the prevalence of UTIs in those who had 
amoxicillin clavulanic acid (Augmentin) vs. those who had levofloxacin (Levaquin) (χ2 = 
13.102, df = 2, P = .001). Vulvovaginal candidiasis reported symptom findings also 
proved significant, as the Augmentin cohort had more complaints than any other 
antibiotic group (χ2 = 30.010, df = 10, P = .001).  
Implications: The project findings reinforced the need for prudence when 
considering prophylactic antibiotic use in the postoperative period. While more research 
is needed to explore antibiotic treatment options further, the data collected and analyzed 
provided novel evidence to guide the decrease of unwanted UTIs in this population. Most 
notably, this project proved Augmentin is not the ideal choice for UTI prophylaxis in this 
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population because of the high number of proven UTIs found, and the statistically high 
prevalence of vulvovaginal candidiasis-related complaints. 
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Introduction 
 Approximately 200,000 women undergo surgery for pelvic floor reconstruction 
each year (Boyles, Weber, & Meyn, 2003). Over 10 percent of women are expected to 
seek surgical intervention for pelvic floor prolapse or incontinence by the age of 80 
(Sutkin, Alperin, Meyn, Wiesenfeld, Ellison, & Zyczynski, 2010). The most common 
morbidity associated with pelvic floor reconstructive and incontinence surgery is urinary 
tract infections (UTIs) (Sutkin et al., 2010). Pelvic floor reconstructive surgery requires 
manipulation of instruments at and near the urethra. While the bladder and urethra are 
clean, the vagina and anus are not; all structures are close in proximity, leading to 
potential contamination, offering support to the relevance of this topic. Another factor 
that impacts UTIs in this population is the risk for incomplete bladder emptying 
postoperatively. Whether by denervation of the bladder secondary to a hysterectomy, 
postoperative swelling, narcotics and anesthetics, or midurethral sling placement, women 
may develop urinary retention, which increases their chances of developing a UTI 
(Sutkin et al., 2010).  
Lastly, the use of a catheter raises the risk of a UTI postoperatively. Seventy to 
eighty percent of complicated UTIs in the United States annually are associated with 
indwelling urinary catheters, which accounts for one million UTIs per year (Flores-
Mireles, Walker, Caparon, & Hultgren, 2015). Female patients undergoing pelvic floor 
reconstructive surgery may have a catheter placed in surgery that remains indwelling for 
several days postoperatively. For this reason, prophylactic antibiotics are often prescribed 
to prevent UTI occurrence in the postoperative period (defined as six weeks).  
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The purpose of this project was to determine the most effective prophylactic 
antibiotic to decrease the number of patients who have UTIs after pelvic floor 
reconstructive surgery in a gynecological reconstructive surgery practice. This 
retrospective chart review yields data on female pelvic floor reconstructive surgery 
patients who have a catheter, and compares effectiveness of prophylactic treatment of 
fluoroquinolones versus other antibiotics.  
Literature Review 
 The literature review process relied on several search engines, including Medline, 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane, 
PubMed, National Center for Biotechnology Information (NCBI), and EBSCOhost for 
pertinent evidence-based research data. The peer-reviewed articles were examined to 
support data found. There were many keywords that demonstrated their use in the search 
for empirical literature, including UTIs, postoperative complications, pelvic floor 
reconstructive surgery, fluoroquinolones, prophylactic use of antibiotics, vaginal surgery, 
anti-incontinence surgery, midurethral sling surgery, catheter-associated urinary tract 
infections, and antibiotic resistance. The data collected was largely from the past five 
years. Limitations in the amount of data found required broadening the search, including 
references dating back to 2003.  
 Inclusion criteria determined for targeting the researched population for this 
project include the following: (a) adult, female participants, (b) who have undergone at 
least one of the following, cystocele repair with anterior colporrhaphy, rectocele repair 
with posterior colporrhaphy, enterocele repair with posterior colporrhaphy, or 
sacrospinous colpopexy. Patients must also (c) have a catheter (transurethral catheter or 
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suprapubic tube), (d) and vaginal packing. Criterion that exclude potential patients are (a) 
those that had any mesh removed at the time of pelvic floor reconstructive surgery, and 
(b) those who exclusively had a colpoperineorrhaphy.  Patients with prior histories of 
recurrent UTIs, those who are postmenopausal, and patients who additionally have a 
urethral sling were also noted, as those variables may impact results. All UTIs were 
proven by straight cath culture in order to be included in the evidence. Secondary 
endpoints that were collected include: self reports of vulvovaginal candidiasis (vaginal 
yeast) infections, confirmed clostridium difficile cases, and how many days from surgery 
those incidents occurred. 
 The theoretical framework for this project was based on a model developed by 
Marita G. Titler that provides foundation and establishes necessary guidance. Titler 
developed the IOWA Model which guided the evidence-based research performed and 
supports its use appropriately in practice (Brown, 2014). The steps to this framework are: 
(1) determine the issue/problem, (2) decide on a plan, (3) create a team, (4) identify 
evidence, (5) analyze the evidence, (6) determine conclusions from the evidence, (7) 
navigate change, (8) decide if change is applicable to practice, (9) implement the change, 
and (10) disseminate results (Brown, 2014). The need for structure to direct the course of 
this project prompted a search for an ideal framework. The IOWA model presents ten 
clear elements that propelled the project from inception through completion.   
The focused problem for this project is the prevalence of UTIs postoperatively. 
Identification of antibiotic effectiveness in preventing UTIs is the second element from 
the selected framework. This quality improvement project was conducted by a women’s 
health nurse practitioner, with the support of an assembled team that included a 
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urogynecologist/gynecological reconstructive surgeon, a doctor of science in 
nursing/family nurse practitioner, an OB/GYN resident physician, and a doctor of 
philosophy in nursing. A thorough review of literature, collection of data, analysis, and 
establishment of conclusions took place prior to determining change implementation, and 
circulation of the findings.    
 Review of the current literature revealed a lack of evidence on the project topic. 
In regard to occurrences of postoperative UTIs, data varied substantially. Findings from 
extant research in this area are equivocal. There are no consistent conclusive results that 
have an answer to the purpose of this project. 
According to Mueller et al. (2016), in examining postoperative patients after 
pelvic floor reconstructive surgery, an observational study concluded that 66% of 
postoperative complications occurred in the first two weeks after surgery and 46% of 
those complications were UTIs.  The research included a sample size of 396 women; 125 
of the women had postoperative complications (Mueller et al., 2016). Guldberg et al. 
(2014) studied a larger population of 2,151 women after having surgery for urinary 
incontinence, rather than pelvic floor reconstructive surgery. The findings showed that 
within the first 60 days postoperatively, 26% of patients who had a history of UTIs 
redeemed an antibiotic prescription for a possible UTI (Guldberg et al., 2014).  Only 11% 
of preoperative non-users of antibiotics to treat UTIs, which was a total of 182 patients, 
received a prescription for antibiotics for a possible UTI during the 60 days immediately 
following surgery. This evidence supports the plan to note all patients with prior UTIs. 
A journal article published in 2008 reviewing relevant randomized controlled 
trials (RCTs) evaluated the UTI prevalence after pelvic floor operations. The findings 
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from the review of nineteen studies gathered that incidences of UTIs for those receiving 
placebos after pelvic floor surgery ranged from 10-64%. (Falagas, Athanasiou, Iavazzo, 
Tokas, & Antsaklis, 2008). Alternatively, the UTI occurrence was 0-15% in those who 
received cephalosporins, which was identified as being the optimal regimen in UTI 
prevention after pelvic floor surgery (Falagas et al., 2008). Falagas et al. (2008) also 
concluded rates of UTIs were 13.6% higher in those treated with ampicillin/sulbactam, 
27.2% with ciprofloxacin, 10-22.7% with metronidazole, 20% with metronidazole plus 
ampicillin, and 28% higher with cotrimoxazole. A study by Swartz et al. (2010), reported 
that there was no significant difference in UTI occurrence after midurethral sling surgery 
in those who received prophylactic antibiotics (3 days of cephalexin, fluoroquinolone, or 
doxycycline), and those who received no antibiotic. Although there was not a urine 
culture for every recorded UTI, the results revealed no difference (P = 0.03), except that 
there were more low-grade adverse events relating to antibiotic use in those in the 
prophylactic antibiotic cohort (Swartz et al., 2010). 
While the information accumulated may cause presumptions, it is important to 
acknowledge some of the weaknesses in the literature. Many of the studies are examining 
different types of surgeries, including generalized pelvic floor surgery, anti-incontinence 
surgery, and reconstructive vaginal surgery. All the variations of what surgery was 
performed, how it was performed, who performed it and who it was performed on are all 
considerations that have significance. Likewise, not all the UTIs reported in the 
documentation were confirmed by urine culture. Some of the reported UTIs were based 
on self-report and others were assumed from urinalysis for bacteria, nitrates, and 
leukocyte esterase. While symptoms such as urinary frequency, urgency, and burning on 
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urination may be present, that is not definitive of an infection. Abnormal urinalysis 
results can appear as a result of the collection technique and, by controlling these 
variables, firm evidence can result. Furthermore, not all patients studied had a catheter, or 
had a catheter for at least 7 days. 
In this review, antibiotics and their strengths and weaknesses were researched and 
observed more closely. A randomized controlled trial assessing nitrofurantoin (Macrobid) 
prophylaxis in catheterized patients after pelvic reconstructive surgery with 159 
participants concluded that prophylactic Macrobid daily does not reduce the risk for 
postoperative UTIs (Dieter et al., 2014). Dieter et al. (2014) looked at the three weeks 
immediately following surgery; results indicated 22% of the 81 patients receiving 
Macrobid and 13% of the 78 patients given the placebo had UTIs, either suspected or 
culture-proven. Conversely, Jackson et al., (2013) found that a three-day course of 
prophylactic Macrobid after surgery for midurethral sling placement was significant (P = 
.04) to decrease postoperative UTIs. The randomized, double-blinded, placebo-
controlled, multicenter trial enrolled 149 subjects and measured UTI prevalence by 
meeting certain symptomatology; UTIs were not culture-proven (Jackson et al., 2013). 
Moreover, another study looked at 449 subjects, 211 randomized to Macrobid, and 224 
randomized to placebo, after pelvic organ prolapse and/or urinary incontinence surgery 
with suprapubic catheterization (Rogers et al., 2004). Findings included a significant 
decrease in culture-proven UTIs in those who received Macrobid (P = 0.002) at the time 
of suprapubic tube removal, but not at the 6-8-week postoperative check-up (Rogers et 
al., 2004).  
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Sutkin et al. (2010) concluded that prolonged duration of catheterization (>10 
days after surgery) is significant to cause UTIs, despite antibiotic prophylaxis. In a 
retrospective chart review of 394 women who had undergone surgery for pelvic floor 
prolapse or stress incontinence, it was found that there was a significantly higher 
prevalence of UTIs in the six-week postoperative period the longer there was a catheter 
in, or clean intermittent self-catheterization (CSIC) was practiced (Sutkin et al., 2010).  
While many limitations have been acknowledged, there are also strengths present. 
By recognizing sensitivities, a better understanding of the functioning of antibiotics can 
be assessed to provide sufficient prophylactic outcomes for patients. The data collected 
has suggested that postoperative complications, including UTIs, will likely materialize 
shortly after surgery, rather than weeks out; this evidence can be compared to future data 
collection to determine relevance. With the nature of pelvic floor reconstructive surgery, 
the anatomical location of the urethra and its adjacency to other contaminated structures 
pose increased risk to the patients’ likelihood of developing a UTI.   
Methods 
 The purpose for this project is based on the postulate that comparing 
postoperative antibiotic effectiveness will result in action to reduce the number of 
postoperative UTIs.  The approach was a retrospective design that, by utilizing evidence-
based practice and data collection, has the potential to implement change. The goal of 
achieving the greatest outcome for the population researched, with the least amount of 
adverse effects possible, is of highest priority. The setting for the project was a healthcare 
facility in Saint Louis, Missouri. Approximately two years of data collectively was 
synthesized from a convenience sample of 732 female patients who underwent pelvic 
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floor reconstructive surgery in the years 2015 through 2017. All patients included had 
pelvic floor reconstructive surgery, and also may or may not have a midurethral sling 
placed for stress urinary incontinence. Patients also had a temporary catheter 
(transurethral or suprapubic) and vaginal packing postoperatively. Patients that have 
additionally undergone any type of mesh removal, and those having only a 
colpoperineorrhaphy, were not included in the dataset.  
Institutional Review Board training for the facility setting and for the University 
of Missouri Saint Louis was obtained. Data collection occurred from the electronic health 
records (EHR) system as a retrospective medical record review; every patient was 
assigned a number to de-identify personal information. A master log with patient names 
and assigned numbers was protected and maintained at the healthcare facility. Data 
collected included: age of subject at time of surgery, type of reconstructive surgery the 
subject underwent, postoperative antibiotic prescribed, length of time the catheter was in, 
if they had a proven UTI infection during the postoperative period, how many days after 
surgery the UTI occurred, the bacteria responsible for the UTI, the antibiotics resistance 
and susceptibility, if the patient is postmenopausal, if the patient has a prior history of 
UTIs, and if the patient has a urethral sling. All data collected was compiled on a 
spreadsheet for analysis. The data was then converted into an SPSS spreadsheet and tests 
including frequencies and chi-squares were performed to analyze the information.  
Results 
 Several outcomes were identified through this process. When comparing 
effectiveness of antibiotics for UTI prophylaxis, it became clear that certain antibiotics 
were more adequate. Out of 732 patients, 315 took a fluoroquinolone (Levaquin = 312; 
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Ciprofloxacin = 3), 414 took either Augmentin (n = 326), Bactrim (n = 38), or Macrobid 
(n = 50), and 3 subjects received no antibiotic. Only 4 subjects who took a 
fluoroquinolone got a UTI. Twenty-seven subjects got a UTI after taking one of the other 
antibiotics; this finding was statistically significant (χ2 = 12.119, df = 1, P = .000). 
Augmentin users had the highest prevalence of postoperative UTIs (n = 23). This finding 
was also statistically significant at χ2 = 11.378, df = 1, P = 0.001. When then comparing 
Augmentin to those taking fluoroquinolones, the same significant result was found. After 
breaking down the analysis to the two largest antibiotic groups prescribed in the practice, 
further outcomes were explored between the Augmentin and Levaquin cohorts (see 
Appendix A). The Levaquin users (n = 312) had 4 UTIs and the Augmentin users (n = 
326) had 23 UTIs. This finding was statistically significant (χ2 = 13.102, df = 2, P = 
.001). Further examination of the demographics of the Levaquin and Augmentin cohorts 
can be found in Appendix A. 
 Other parallels explored included examining the possible correlation between 
proven UTIs and postmenopausal status, prior history of UTIs, having a current mid-
urethral sling, having a hysterectomy as part of their surgery, and the length of time the 
catheter was in. Of note, there was significance in those with prior histories of UTIs, 
those with a mid-urethral sling, and those with a catheter in longer than 10 days (see 
Appendix B). When considering the length of time the catheter was in, only 11 UTIs 
occurred within 10 days of surgery, whereas 20 UTIs were confirmed in those who had 
the catheter longer than 10 days.  Of the 31 UTIs identified, Escherichia coli was the 
responsible bacteria for 10 of the infections (32.3%). Then, after acknowledging the most 
frequent UTI-causing bacteria, it led to the analysis of the most resistant and susceptible 
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antibiotic choices for the UTIs. The three antibiotics that the 31 infections were most 
frequently susceptible to were Tobramycin (n = 28), Gentamicin (n = 29), and Cefepime 
(n = 26). Of the antibiotics that were prescribed postoperatively, here is the bacteria 
susceptible[s] vs. resistant[r] breakdown: Levaquin (n = 24[s]/2[r]), Augmentin (n = 
15[s]/3[r]), Bactrim (n = 17[s]/5[r]), Macrobid (n = 21[s]/2[r]), and Ciprofloxacin (n = 
23[s]/5[r]). Conversely, the antibiotics with the highest frequency of resistance were 
Ampicillin (n = 12) and Tetracycline (n = 7).    
 Lastly, the self-reports of vulvovaginal candidiasis infections requiring medicinal 
treatment and the incidents of clostridium difficile were investigated. Of the population 
researched, there were no confirmed cases of clostridium difficile. There were however 
48 subjects treated for a vulvovaginal candidiasis infection.  Of the 48 yeast episodes, 
there was a statistical finding of χ2 = 30.010, df = 10, P = .001 of those who had taken 
Augmentin postoperatively (see Appendix D).  
Discussion 
 The findings from this study suggested that fluoroquinolone use for the 
prophylactic treatment of UTIs is superior to other antibiotics. More specifically, 
Levaquin is a preferred treatment, in regard to the prevention of UTIs and shows a fairly 
small risk for vulvovaginal candidiasis infections, when compared to Augmentin. 
Although other antibiotics were included, as well as 3 subjects that received no antibiotic, 
the proportion of subjects given Augmentin and Levaquin was far greater. Then, 
comparing those two cohorts, we must take into consideration the potential differences in 
the populations that could contribute to these findings. When matching the populations 
side-by-side, it was evident only few differences were found.  
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 When considering the implications these results have on practice, it is important 
to weigh the risks vs benefits of the antibiotic options. While Levaquin had a 
significantly lower rate of postoperative UTIs, it does have a black box warning for 
tendon rupture (Tanne, 2008). Evidence from this study points to the superiority of 
Levaquin, but other risks must be calculated when prescribing is considered. Augmentin 
was identified as having a poor ability to prevent UTIs and a high incidence of 
vulvovaginal candidiasis complaints, leading to the inference that it may not be the ideal 
postoperative treatment of choice either. It would be beneficial to conduct future research 
comparing the Bactrim and Macrobid more closely, because this project had limited 
patients on these antibiotics. However, from the narrow cohorts investigated, the 
drawbacks seemed low. 
Conclusion 
This project demonstrated that there are both advantages and disadvantages to 
varying antibiotics in the postoperative period. In order to establish the greatest care for 
this patient population, clinicians must place emphasis on the preventative abilities of 
individual antibiotics relating to UTIs, as well as the negative effects of each medication. 
The evidence needs to be compiled and considered when making changes or maintaining 
current treatment regimens. This study showed a large difference in the prevention 
capabilities between Levaquin and Augmentin, but data was limited on Ciprofloxacin, 
Macrobid, and Bactrim. While acknowledging the robust data from the fluoroquinolone 
class, it must also be noted that this is not the only data to consider when prescribing a 
prophylactic antibiotic to a patient. The black box warning, however rare, is cautionary 
and must also be weighed when choosing the proper treatment for an individual.  
  
 
ANTIBIOTIC PROPHYLAXIS FOR URINARY TRACT INFECTIONS                   16 
The findings support the need to amend the prescribing patterns to avoid 
Augmentin and consider more frequent prescribing of Bactrim and Macrobid. 
Discriminating amongst the high and low risk factors to prevent postoperative UTIs in 
this population is also key. It would be appropriate to consider using Levaquin in 
populations found to be at a higher risk for a postoperative UTI, including those with a 
prior history of UTIs and those who plan to have a midurethral sling/suprapubic tube 
placed for stress urinary incontinence. 
Ultimately, much light was shed on the pitfalls of some antibiotic choices, most 
notably Augmentin, and leads to the need for further research to identify the optimal 
choice for UTI prevention in the pelvic floor reconstructive surgical patient.    
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Appendices 
Appendix A 
Fluoroquinolones vs. Other Antibiotics - Cohort Comparison 
Variables Fluoroquinolones Other Antibiotic P-Value 
Postmenopausal 243/315 (77.1%) 312/414 (75.4%) .576 
Midurethral Sling/SPT 153/315 (48.6%) 186/414 (44.9%) .326 
Hysterectomy 157/315 (49.8%) 204/414 (49.3%) .880 
History of UTIs 78/315 (24.8%) 108/414 (26.1%) .684 
Catheter >10 days 93/315 (29.5%) 111/414 (26.8%) .419 
The p-value was set to <.05.  
 
Levaquin vs. Augmentin - Proven UTI Crosstabulation 
 Antibiotic  
Proven UTI 
Total 
Yes No 
Other 4 90 94 
Levaquin 4 308 312 
Augmentin 23 303 326 
Total 31 701 732 
 
Chi-Square Tests - Levaquin vs. Augmentin 
 Value df Asymptotic Significance (2-sided) 
Pearson Chi-Square 13.102a 2 .001 
Likelihood Ratio 14.512 2 .001 
Number of Valid Cases 732   
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Levaquin vs. Augmentin - Cohort Comparison 
Variables Levaquin Augmentin P-Value 
Postmenopausal 240/312 (76.9%) 243/326 (74.5%) .716 
Midurethral Sling/SPT 151/312 (48.4%) 141/326 (43.3%) .270 
Hysterectomy 157/312 (50.3%) 162/326 (49.7%) .734 
History of UTIs 76/312 (24.4%) 75/326 (23.0%) .009* 
Catheter >10 days 93/312 (29.8%) 78/326 (23.9%) .030* 
These are individual chi-squares. 
The p-value was set to <.05. *Denotes significant finding 
 
Appendix B 
Association of UTIs with Postoperative Antibiotics and Other Factors 
Variable Chi-Square P-Value 
Prior History of UTIs (n = 17) 14.603 < .0001* 
Catheter in Longer than 10 days (n = 20) 21.402 < .0001* 
Current Midurethral Sling (n = 22) 7.824 .005* 
Post-op Antibiotic = Augmentin (n = 23) 11.378 .001* 
Postmenopausal (n = 25) .390 .532 
Surgery Included a Hysterectomy (n = 15) .019 .891 
These are individual chi-squares. The df was 1 for each of these crosstabulations.  
The p-value was set to <.05. *Denotes significant finding 
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Appendix C 
Transurethral vs. Suprapubic - Cohort Comparison 
Variable 
Transurethral 
n = 392 (53.6%) 
Suprapubic 
N = 340 (46.4%) P-Value 
Age (Years) 61 (29-86) 59 (28-85) .466 
Postmenopausal 307/392 (78.3%) 249/340 (73.2%)  .109 
Prior history of UTIs 100/392 (25.5%) 87/340 (25.6%) .981 
Incidence of UTIs 9/392 (2.3%) 22/340 (6.5%) .005* 
Catheter > 10 days 2/392 (0.5%) 203/340 (59.7%) < .0001* 
These are individual chi-squares.  
The p-value was set to <.05. *Denotes significant finding 
 
Appendix D 
Vulvovaginal Candidiasis Crosstabulation 
Postoperative Antibiotic 
Vaginal Yeast Infection  
Total 
Yes No 
Levaquin 7 305 312 
Augmentin 39 287 326 
Bactrim 0 38 38 
Ciprofloxacin 0 3 3 
Macrobid 2 48 50 
Total 48 684 732 
Chi-Square Tests - Vulvovaginal Candidiasis Infections 
 Value df Asymptotic Significance (2-sided) 
Pearson Chi-Square 30.010a 10 .001 
a. 12 cells (66.7%) have expected count less than 5. The minimum expected count is .00. 
 
